Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

Ironwood Pharmaceutical, Inc.

Daniel P Zimmer

Mark G Currie

Angelika Fretzen

Marco Kessler

Brian Cali

Timothy Claude Barden

John Jeffrey Talley

Paul A Renhowe

Joel D Moore

Rajesh R Iyengar

Takashi Nakai

Nicholas Robert Perl

G Todd Milne

G-Yoon Jamie Im

Charles Kim

Peter Scott Yorgey

Wayne Schairer

Eduardo Martinez

Stephen Antonelli

Regina Lundrigan-Soucy

Jing-Jing Yang

Paul Allan Renhowe

Brian M Cali

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.

Treatments for gastrointestinal disorders

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.

The present invention provides new uroguanylin derivatives that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.

Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.

Treatments of gastrointestinal disorders

Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.

Methods and compositions for the treatment of heart failure and other disorders

Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.

4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.

Growing community of inventors

Somerville, MA, United States of America

Daniel P Zimmer